Boston Scientific Corp. Stock (US10117L1017): BTIG Reaffirms Buy Rating And $65 Price Target

BTIG has reiterated its Buy rating and $65.00 price target on Boston Scientific, while valuation metrics from GuruFocus and a "Moderate Buy" consensus keep the medtech stock in focus for US investors.

Responsible: ad hoc news Earnings Desk. Reviewed prior to publication on June 16, 2026 at 6:58 PM ET. Details in the imprint.

BTIG has reaffirmed its Buy rating on Boston Scientific Corp., maintaining a $65.00 price target as of June 16, 2026, keeping the medtech group firmly on Wall Street's radar. The call comes against a backdrop of broadly positive analyst sentiment, with MarketBeat data showing a "Moderate Buy" consensus rating and an average target price of $85.08 for the stock. At the same time, valuation metrics from GuruFocus indicate that Boston Scientific's current share price around $46.76 sits well below an estimated GF Value of $105.28, suggesting significant upside potential based on that model. For US retail investors, the combination of reiterated analyst support and a sizable valuation gap keeps the Nasdaq-listed BSX shares in focus.

BTIG reiterates Buy rating and holds $65 price target

According to a June 16, 2026 update highlighted by GuruFocus, BTIG analyst Marie Thibault has reiterated a Buy rating on Boston Scientific (ticker: BSX) and maintained her 12-month price target at $65.00. The note follows an earlier rating update first issued in October 2023, and the reaffirmation signals continued confidence in the company's fundamentals and growth pipeline. BTIG's stance places its target moderately above the current share price but still below the higher average target reported across the broader analyst community, underlining a constructive yet not aggressive outlook on the medtech name.

The BTIG report, as summarized by GuruFocus, points to Boston Scientific's position in minimally invasive medical devices and the company's execution across its core segments as key supports for the Buy recommendation. While the full BTIG research note is paywalled, the reiterated target and rating indicate that the analyst sees no material change that would warrant a downgrade or a major revision of expectations. As of the latest data, the $65.00 target implies substantial upside from the stock's current trading level in the mid-$40 range, though still below some of the more optimistic targets embedded in the consensus.

GuruFocus also highlights that, based on its proprietary GF Value framework, Boston Scientific shares trade at a notable discount to intrinsic value. The GF Value for BSX is cited at $105.28, versus an actual share price around $46.76, which would correspond to an estimated 55.6 percent undervaluation on that model. While GF Value is one of many valuation tools and rests on its own assumptions, the magnitude of the gap helps explain why multiple analysts, including BTIG, maintain constructive ratings even after a multi-year run in medtech equities.

Analyst consensus remains positive on Boston Scientific

Beyond the BTIG call, aggregated data from MarketBeat indicate that Boston Scientific currently carries a "Moderate Buy" consensus rating among Wall Street analysts. The platform reports that the average 12-month price target across covering firms stands at approximately $85.08, comfortably above BTIG's $65.00 figure and far above the stock's present price in the mid-$40s. This spread between consensus targets and the market quote reflects persistent optimism on Boston Scientific's earnings trajectory and product portfolio.

MarketBeat data also show broad institutional interest in the stock, with Oddo BHF Asset Management Sas recently increasing its stake by 25.7 percent in the fourth quarter. The asset manager ended the period with 567,904 shares valued at about $54.15 million, highlighting that European institutions as well as US funds continue to see Boston Scientific as an attractive medtech exposure. Such stake-building by professional investors often complements positive analyst views and reinforces the perception of the company as a core holding within the medical devices segment.

In parallel, Boston Scientific continues to invest in its physical footprint and supply capabilities. Industry outlet Supply Chain Dive recently reported that the company plans to build a new distribution center in Indiana to support global logistics for its medical devices. The facility, to be located near an existing principal manufacturing site, is intended to streamline distribution and improve service levels for hospitals and health systems. While not directly tied to the BTIG rating, this infrastructure expansion aligns with longer-term growth plans and can support revenue scalability if demand continues to rise.

Valuation signals: implied upside from GF Value and targets

Valuation tools provide another lens on Boston Scientific's current positioning. GuruFocus calculates a GF Value of $105.28 for BSX, which incorporates historical valuation multiples, past returns, and analyst estimates into a blended intrinsic value estimate. With the stock trading around $46.76, the model suggests that shares are significantly undervalued, labeling the gap as a 55.6 percent discount to the estimated fair value. It is important to note that this is a model-based figure and does not guarantee future returns, but it underscores how far market pricing sits below some fundamental assessments.

The analyst-target picture complements this valuation view. The $65.00 BTIG target, while below the $85.08 consensus average cited by MarketBeat, still points to double-digit percentage upside from the current share price. Consensus targets can change quickly in response to earnings or guidance, yet the current spread between the mid-$40s trading level and mid-$60s to mid-$80s target range suggests that analysts, on balance, believe earnings and cash flows will grow sufficiently to justify higher valuations over the coming 12 months.

Investors watching the stock may therefore weigh two distinct but broadly aligned signals: a proprietary valuation model that flags substantial undervaluation, and Wall Street research that continues to cluster around Buy or equivalent ratings with targets comfortably above spot prices. Both perspectives depend heavily on Boston Scientific's ability to execute on its pipeline and maintain margins in a competitive medtech landscape, but they provide a reference point for how professional observers currently frame the risk-reward profile.

Business profile and supply-chain expansion add context

Boston Scientific is widely recognized as a major global manufacturer of minimally invasive medical devices, serving specialties that include cardiology, electrophysiology, endoscopy, neuromodulation, and urology. The company develops, produces, and markets products such as stents, catheters, cardiac rhythm management systems, and various implants used in interventional procedures. This diversified product base gives Boston Scientific exposure to both elective and urgent procedures, helping to balance cyclical swings in hospital utilization.

Finanzen.net describes Boston Scientific as a leading medtech player with a broad portfolio of therapeutic solutions and devices deployed worldwide. Revenue is driven by procedure volumes, product innovation, and geographic expansion, with hospitals and clinics across North America, Europe, and emerging markets forming the core customer base. This structure places the company in the heart of long-term healthcare trends like aging populations, rising prevalence of chronic disease, and continued adoption of minimally invasive procedures.

On the operational side, the planned Indiana distribution center reported by Supply Chain Dive suggests that Boston Scientific is preparing for sustained global demand growth and aiming to optimize its logistics network. The site is expected to support global distribution for the firm's medical devices and sits near a major manufacturing hub, which can help lower lead times and enhance inventory management. In the medtech industry, reliable and efficient distribution is a competitive asset, as hospitals and physicians depend on timely access to devices for scheduled and emergency interventions.

Corporate information available via the company's own website shows that Boston Scientific is headquartered in Marlborough, Massachusetts and maintains a broad manufacturing and R&D footprint across the United States and internationally. The stock is listed on the New York Stock Exchange under the ticker symbol BSX, and it is widely followed as a large-cap component within major healthcare and medtech indices. Trading is conducted in US dollars, making the stock directly accessible for US retail investors through standard brokerage accounts.

For now, the mix of a reiterated Buy rating from BTIG, a supportive consensus backdrop, and model-based indications of undervaluation keeps Boston Scientific Corp. on the radar for market participants focused on the medical devices space. How the stock ultimately performs will depend on upcoming earnings reports, regulatory developments, and the company's ability to turn its product pipeline and supply-chain investments into sustained revenue and profit growth.

Boston Scientific at a glance

• Name: Boston Scientific Corp.
• Industry: Medical devices, minimally invasive therapies
• Headquarters: Marlborough, Massachusetts, United States
• Core markets: Cardiology, cardiac rhythm management, endoscopy, neuromodulation, urology, and related minimally invasive procedures
• Revenue drivers: Hospital and clinic procedure volumes, adoption of minimally invasive devices, product innovation and pipeline launches, geographic expansion
• Listing: New York Stock Exchange, ticker BSX
• Trading currency: US dollar (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.